Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor (None standardized for all three together; typically abbreviated as ADRA1A, ADRA1B, ADRA1D for individual subtypes)

Alpha-1A, Alpha-1B, and Alpha-1D adrenergic receptors are members of the alpha-1 adrenergic receptor family, a subgroup of G protein-coupled receptors that respond to catecholamines (adrenaline, noradrenaline)[2][3][7]. These receptors are structurally related but display differences in tissue distribution, physiological role, and pharmacological profile. Alpha-1A is predominant in the prostate and lower urinary tract, Alpha-1B is prominent in vascular smooth muscle (modulating blood pressure), and Alpha-1D contributes to vascular tone and may have roles in the CNS[1][2][3]. Upon activation, they trigger Gq protein signaling cascades leading to phospholipase C activation, inositol phosphate (IP3/DAG) production, and increased intracellular calcium, resulting in smooth muscle contraction. These targets are clinically relevant in the management of hypertension, benign prostatic hyperplasia, and related disorders, with multiple alpha-1 antagonists and a few subtype-selective agents in clinical use[2][3][6][7]. Subtype selectivity is a major goal in drug development to maximize efficacy and minimize adverse effects.

Other names

α1A-adrenoceptor, α1B-adrenoceptor, α1D-adrenoceptor (or alpha-1A, -1B, -1D adrenoceptors)ADRA1A, ADRA1B, ADRA1D (gene/protein nomenclature)Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor

Antagonists block receptor-mediated smooth muscle contraction, leading to vasodilation, reduced blood pressure, and smooth muscle relaxation in the prostate and bladder neck Agonists stimulate Gq-coupled signaling, leading to increased intracellular calcium and smooth muscle contraction Some drugs demonstrate subtype selectivity, allowing organ-selective therapy (e.g., tamsulosin for prostate)